PL438213A1 - Kompozycja farmaceutyczna zawierająca antagonistę aldosteronu i diuretyk pętlowy oraz dopuszczalne farmaceutycznie substancje pomocnicze - Google Patents
Kompozycja farmaceutyczna zawierająca antagonistę aldosteronu i diuretyk pętlowy oraz dopuszczalne farmaceutycznie substancje pomocniczeInfo
- Publication number
- PL438213A1 PL438213A1 PL438213A PL43821321A PL438213A1 PL 438213 A1 PL438213 A1 PL 438213A1 PL 438213 A PL438213 A PL 438213A PL 43821321 A PL43821321 A PL 43821321A PL 438213 A1 PL438213 A1 PL 438213A1
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutically acceptable
- aldosterone antagonist
- pharmaceutical composition
- loop diuretic
- acceptable excipients
- Prior art date
Links
- 229940083712 aldosterone antagonist Drugs 0.000 title abstract 3
- 239000002170 aldosterone antagonist Substances 0.000 title abstract 3
- 239000002171 loop diuretic Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 229960001208 eplerenone Drugs 0.000 abstract 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical group C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
- 229960003883 furosemide Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008247 solid mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Przedmiotem zgłoszenia jest kompozycja farmaceutyczna zawierająca antagonistę aldosteronu i diuretyk pętlowy oraz dopuszczalne farmaceutycznie substancje pomocnicze, charakteryzującą się tym, że antagonistę aldosteronu stanowi eplerenon, diuretyk pętlowy stanowi furosemid, a kompozycja ma postać stałej mieszaniny zawierającej od 2% do 12% wagowo wymienionych substancji czynnych, od 1% do 10% wagowo co najmniej jednej polimerowej substancji wiążącej oraz co najmniej 40% wagowo rozpuszczalnej(-ych) w wodzie substancji wypełniającej(-ych).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL438213A PL244821B1 (pl) | 2021-06-18 | 2021-06-18 | Kompozycja farmaceutyczna zawierająca antagonistę aldosteronu i diuretyk pętlowy oraz dopuszczalne farmaceutycznie substancje pomocnicze |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL438213A PL244821B1 (pl) | 2021-06-18 | 2021-06-18 | Kompozycja farmaceutyczna zawierająca antagonistę aldosteronu i diuretyk pętlowy oraz dopuszczalne farmaceutycznie substancje pomocnicze |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL438213A1 true PL438213A1 (pl) | 2022-12-19 |
| PL244821B1 PL244821B1 (pl) | 2024-03-11 |
Family
ID=84487946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL438213A PL244821B1 (pl) | 2021-06-18 | 2021-06-18 | Kompozycja farmaceutyczna zawierająca antagonistę aldosteronu i diuretyk pętlowy oraz dopuszczalne farmaceutycznie substancje pomocnicze |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL244821B1 (pl) |
-
2021
- 2021-06-18 PL PL438213A patent/PL244821B1/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL244821B1 (pl) | 2024-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4574906A3 (en) | Pharmaceutical composition | |
| DE60114467D1 (de) | Zubereitungen enthaltend ein steroidhormon und ein stabilisierungsmittel in nicht-kristalliner form | |
| WO2004066910A8 (en) | Controlled release modifying complex and pharmaceutical compositions thereof | |
| NO20071853L (no) | Farmasoytisk sammensetning inneholdende en fast dispersjon med en polymermatriks inneholdende en jevn polydekstrosefase og en jevn fase av en polymer forskjellig fra polydekstrose. | |
| HRP20110169T1 (hr) | Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c | |
| BR112022010891A2 (pt) | Combinação de um antagonista do receptor lpa1 de azetidina com agentes antifibróticos | |
| HRP20040996B1 (hr) | Tablete visokog sadržaja lijeka | |
| MXPA04005104A (es) | Regimen de dosificacion y composicion farmaceutica para anticoncepcion de emergencia. | |
| HRP20231670T1 (hr) | Farmaceutski pripravak za oralnu primjenu koji sadrži derivat aminopirimidina ili njegovu sol | |
| CR20210156A (es) | Administración sostenida de polipéptidos similares a la angiopoyetina 3 | |
| PL438213A1 (pl) | Kompozycja farmaceutyczna zawierająca antagonistę aldosteronu i diuretyk pętlowy oraz dopuszczalne farmaceutycznie substancje pomocnicze | |
| AR046226A1 (es) | Formulaciones farmaceuticas que contienen saborizante con caracteristicas farmaceuticas mejoradas | |
| HRP20080252T3 (hr) | Oralni antimikrobni farmaceutski pripravci | |
| BR112022010976A2 (pt) | Produtos oral com liberação controlada | |
| HRP20050342B1 (hr) | Farmaceutska formulacija olanzapina | |
| EA200500672A1 (ru) | Содержащие альфузозин композиции с отсроченным высвобождением | |
| EP4674435A3 (en) | Composition having improved voluntary acceptance | |
| DE602005025339D1 (de) | Flavonoide und Tocotrienole enthaltende Zusammensetzungen und deren Verwendungen | |
| WO2023027670A3 (en) | Lyophilized levosimendan compositions | |
| MX2020002210A (es) | Composicion farmaceutica estabilizada que comprende un antagonista competitivo especifico del receptor colinergico. | |
| MX2021004553A (es) | Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda. | |
| PL432480A1 (pl) | Preparat eplerenonu w postaci tabletek ulegających rozpadowi w jamie ustnej | |
| AR051098A1 (es) | Emulsiones medicinales refrescantes | |
| BRPI0416154A (pt) | combinação de antagonistas t1, amilorida ou triamterina, e um diurético | |
| EA200702386A1 (ru) | Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения |